Bial - Portela & Cª, S.A. is a Portuguese pharmaceutical company headquartered in Lisbon, Portugal, with operations in over 50 countries. Founded in 1914, Bial has established itself as a leader in central nervous system disorders, particularly in epilepsy and Parkinson's disease[1].
The company's most notable achievement is the development of opicapone (brand name Ongentys), a COMT inhibitor approved for Parkinson's disease. Bial maintains a focused neuroscience pipeline targeting movement disorders and other CNS conditions[2].
| Program | Target/Mechanism | Indication | Phase | Status |
|---|---|---|---|---|
| Opicapone (Ongentys) | COMT inhibitor | Parkinson's Disease | Approved | Commercial |
| BIA 28-6156 | Alpha-synuclein antibody | Parkinson's Disease | Phase 1/2 | Active |
| BIA 30-908 | Undisclosed | CNS disorder | Discovery | Research |
| BIA 31-457 | Undisclosed | Epilepsy | Preclinical | Research |
Opicapone is a once-daily catechol-O-methyltransferase (COMT) inhibitor approved as an adjunct therapy to levodopa/carbidopa or levodopa/benserazide combinations in adult patients with Parkinson's disease and end-of-dose motor fluctuations[3].
Mechanism of Action:
Clinical Benefits:
Regulatory Status:
BIA 28-6156 is a monoclonal antibody targeting alpha-synuclein in development for Parkinson's disease[4].
Mechanism:
Development:
Bial maintains discovery programs in CNS:
| Program | Target | Indication |
|---|---|---|
| BIA 30-908 | CNS target | Movement disorder |
| BIA 31-457 | Ion channel | Epilepsy |
| Undisclosed | Novel targets | Various CNS |
| Partner | Focus | Status |
|---|---|---|
| Biotie | Acquisition | Completed |
| Academic institutions | Research | Active |
| Global pharma | Commercialization | Various |
Parkinson's Disease Treatment
COMT Inhibitors
AbbVie
Cerevel Therapeutics